Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;25(3):268-273.
doi: 10.1097/MOT.0000000000000753.

Survival in adult lung transplantation: where are we in 2020?

Saskia Bos  1 , Robin Vos  1   2 , Dirk E Van Raemdonck  2   3 , Geert M Verleden  1   2
Affiliations
Review

Survival in adult lung transplantation: where are we in 2020?

Saskia Bos et al. Curr Opin Organ Transplant. 2020 Jun.

Abstract

Purpose of review: In this article, an overview of the survival after lung transplantation will be given, with a focus on factors affecting outcome and differences in survival determined by underlying disease.

Recent findings: Lung transplantation is an established treatment modality for patients with various end-stage lung diseases. The most recent International Society for Heart and Lung Transplantation Registry reports a 1 and 5-year survival of 85 and 59%, respectively, for adult lung transplant recipients transplanted since 2010. Over the past decades, significant improvements in patient outcomes have been achieved related to changes in donor selection, organ preservation, perioperative management and better treatment of postoperative complications. However, long-term graft and patient outcomes still lag behind that of other solid organ transplantations. Chronic lung allograft dysfunction (CLAD) a condition which develops in about 50% of recipients 5 year after lung transplantation, remains the major barrier for long-term survival, although development of solid organ cancer is nowadays also an increasing cause of late mortality.

Summary: Lung transplantation offers a survival benefit in well chosen patients with end-stage lung diseases. However, CLAD, side effects of immunosuppressive therapy and solid organ cancer remain important challenges impairing long-term survival. Advances in prevention and treatment of chronic rejection are critical to further improve outcome.

PubMed Disclaimer

References

    1. Chambers DC, Cherickh WS, Harhay MO, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report – 2019; focus theme: donor and recipient size match. J Heart Lung Transpl 2019; 38:1042–1055.
    1. Erasmus ME, van der Bij W. Death after lung transplantation: improving long term survival despite perilous early postoperative years. Transpl Int 2020; 33:128–129.
    1. Van Raemdonck D, Neyrinck A, Vos R, Verleden GM. Living by numbers. J Thorac Cardiovasc Surg 2018; 156:906–907.
    1. Spratt JR, Brown RZ, Rudser K, et al. Greater survival despite increased complication rates following lung transplant for alpha-1-1-antitrypsin deficiency compared to chronic obstructive pulmonary disease. J Thorac Dis 2019; 11:1130–1144.
    1. Ranganath NK, Malas J, Phillips KG, et al. Single and double lung transplantation have equivalent survival for idiopathic pulmonary fibrosis. Ann Thorac Surg 2020; 109:211–217.